Form 10-Q · Quarterly report
Baxter International 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0000010456
- Accession no.
- 0001628280-26-068278
Summary
Baxter International reported third-quarter 2026 net income attributable to stockholders of $294 million, or $0.57 per diluted share, compared with a $46 million loss a year earlier, as net sales rose 5% to $2.976 billion. For the first nine months, net income attributable to Baxter stockholders was $405 million, or $0.78 per diluted share, compared with $171 million, or $0.33 per diluted share.
Key points
- Third-quarter net sales were $2.976 billion, up 5% from $2.835 billion; U.S. sales rose 3% and international sales rose 7%.
- Nine-month net sales were $8.637 billion, up 4% from $8.270 billion.
- Medical Products & Therapies third-quarter net sales rose 6% to $2.102 billion, with Advanced Surgery up 12% and Infusion Therapies & Platforms up 5%.
- Baxter temporarily stopped distributing and installing Novum LVP in the U.S. and Canada except for medical necessity and expects no meaningful sales of the product while the holds are in effect.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion RESULTS OF OPERATIONS Net income (loss) attributable to Baxter stockholders for the three months ended September 30, 2026 was $294 million, or $0.57 per diluted share, compared to $(46) million, or $(0.09) per diluted share for the three months ended September 30, 2025. For the three months ended September 30, 2026, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $5 million, or $0.01 per diluted share. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.